Hertraz 440 mg Injection

Trastuzumab is a monoclonal antibody that specifically targets the HER2 protein, which is overexpressed on the surface of certain cancer cells and drives their rapid growth and division. By binding to this protein, Trastuzumab helps block the growth signals that HER2 would otherwise send, while also flagging these cancer cells for destruction by the body's immune system. It is commonly used in the treatment of HER2-positive breast cancer, a subtype identified through specific laboratory testing, helping determine which patients are likely to benefit from this targeted approach. Trastuzumab is also used to treat certain HER2-positive stomach and gastroesophageal junction cancers, expanding its role in precision cancer care. It is often used in combination with chemotherapy, particularly in earlier stages of breast cancer treatment, to provide a more comprehensive approach to fighting the cancer. The medication is administered through intravenous infusion, typically in a hospital or specialized oncology setting, allowing healthcare providers to closely monitor the patient during and after administration. Regular monitoring, including heart function tests, is an important part of treatment to help ensure safety throughout the course of therapy. Many patients with HER2-positive cancers experience meaningful tumor response and improved outcomes as part of a comprehensive treatment plan involving Trastuzumab. As with all targeted cancer therapies, Trastuzumab should be administered under the close supervision of an experienced oncology healthcare team.